Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7aaadf1e1524131f3f6b65d42d54da89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ac3d0c5dc3d754391ee78325d924d66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b923fa14bca8c20a64b0e7acf86875c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e6253be96c2cd64fa5972d66eb3f43b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6881 |
filingDate |
2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3b4aedc4ce96e169ed1ec82c6ecc41f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_652d6d196a3367e357fb65cf4335c16e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3da7963ed49124edb7bb0e33be294a7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1324646df30f9ee5c30393e863d2fc6 |
publicationDate |
2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018142305-A1 |
titleOfInvention |
Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types |
abstract |
In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of FOXC1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided. In other embodiments, methods for diagnosing metastatic breast cancer using the expression ratio of FOXC1/FOXA1 in a population of breast cancer tumor cells are provided. The methods also entail administering a treatment for metastatic breast cancer if the expression ratio of FOXC1/FOXA1 in the population of breast cancer tumor cells is elevated as compared to a control. Other embodiments provide methods for treating breast cancer with a proteasome inhibitor alone or in combination with a Wnt inhibitor in subjects with tumor cells expressing FOXC1 in a subject. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110452982-A |
priorityDate |
2009-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |